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Objective The aim of this study was to assess the association between maximum daily atrial fibrillation (AF) burden and risk of is-
chaemic stroke.
Background Cardiac implanted electronic devices (CIEDs) enhance detection of AF, providing a comprehensive measure of AF
burden.
Design, setting,
and patients
A pooled analysis of individual patient data from five prospective studies was performed. Patients without permanent AF,
previously implanted with CIEDs, were included if they had at least 3 months of follow-up. A total of 10 016 patients
(median age 70 years) met these criteria. The risk of ischaemic stroke associated with pre-specified cut-off points of
AF burden (5 min, 1, 6, 12, and 23 h, respectively) was assessed.
Results During a median follow-up of 24 months, 43% of 10 016 patients experienced at least 1 day with at least 5 min of AF
burden and for them the median time to the maximum AF burden was 6 months (inter-quartile range: 1.3–14). A
Cox regression analysis adjusted for the CHADS2 score and anticoagulants at baseline demonstrated that AF burden
was an independent predictor of ischaemic stroke. Among the thresholds of AF burden that we evaluated, 1 h was asso-
ciated with the highest hazard ratio (HR) for ischaemic stroke, i.e. 2.11 (95% CI: 1.22–3.64, P ¼ 0.008).
Conclusions Device-detectedAFburden is associatedwith an increasedriskof ischaemic stroke in a relativelyunselectedpopulationof
CIEDs patients. This finding may add to the basis for timely and clinically appropriate decision-making on anticoagulation
treatment.
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Introduction
Atrial fibrillation (AF)-associated ischaemic stroke can be devastating
and a major contributor to healthcare spending. Fortunately, it is
largely preventable by anticoagulant therapy. Current guidelines rec-
ommend risk-based use of anticoagulant therapy in patients with AF.
Such guidelines apply to patients with paroxysmal as well as persist-
ent AF.1 However, among patients with paroxysmal AF, the fre-
quency and length of episodes of AF are highly variable. Further,
many episodes of AF are clinically ‘silent’, being detected incidentally
through routine physical examinations, pre-operative assessments,
diagnostic logs of implanted devices, or population surveys.2
Current guidelines do not specifically address anticoagulation use
in cases of ‘silent’ AF. Indeed, in some cases, asymptomatic AF is
revealed only after complications such as ischaemic stroke or con-
gestive heart failure have occurred.3
The relationship between the duration and frequency of AF and
stroke risk is uncertain and an area of active investigation. Moreover,
the definition of a clinically useful measure that accurately reflects an
individual risk from an intermittent and progressive disease is a chal-
lenge.4–10 Modern implanted devices such as defibrillators, pace-
makers, or implantable loop recorders now allow precise, continuous
long-term monitoring of heart rhythms, such as AF.2 Implanted
devices with an atrial lead can measure the total time spent in AF
each day, i.e. the daily atrial tachycardia/AF burden or ‘daily AF burden’.
We pooled data from three studies of patients with a broad spec-
trum of such devices to assess the association between the maximum
daily AF burden and the risk of ischaemic stroke in order to provide a
large patient population to be evaluated for this scope.
Methods
Patient population and study design
A pooled analysis of individual patient data from three large prospective
observational studies was performed. Patients were eligible for the
pooled database if they were implanted with a device capable of measur-
ing atrial tachyarrhythmia, had at least 3 months of follow-up and device
diagnostic data available, and did not have permanent AF. Among the 22
433 patients enrolled in the three studies, 10 016 (45%) patients fulfilled
the inclusion criteria. Reasons for patients exclusions were a follow-up
shorter than 3 months in 32%, incomplete diagnostic data coverage of
the follow-up period in 32%, implant of a single-chamber device in
30%, and permanent AF in 6%. Overall, health status at 1-year follow-up
was known for 8515 patients (85% of patients included in this analysis).
The current analysis included results from the TRENDS and PANO-
RAMA studies and the Italian ClinicalServicew Registry Project.
TRENDS (ClinicalTrials.gov identifier: NCT00279981) was a prospect-
ive, observational study designed to assess the relationship between
device-detected atrial tachyarrhythmias and thrombo-embolic events
with 3045 patients enrolled from 116 sites in USA, Canada, and Australia.
PANORAMA (ClinicalTrials.gov.indentifier: NCT00382525) is a pro-
spective, observational study designed to investigate the long-term oper-
ation and clinical outcomes of cardiac rhythm management devices. A
total of 8522 patients were enrolled between January 2005 and July
2011, with the majority of the patients coming from emerging or devel-
oping economies. The Italian ClinicalServicew Project (ClinicalTrials.go-
v.identifier: NCT01007474) is a national cardiovascular data repository
and medical care project aimed at describing and improving the use of
implantable cardiac devices in 150 Italian cardiology centres. Patient re-
cruitment and follow-up is on-going with 10 866 patients included
between January 2004 and July 2011.
PANORAMA and the Italian ClinicalServicew Project are observation-
al studies of clinical care where all treatment decisions (including device
settings, use of concomitant therapies, and medication) are made by
treating physicians. Clinical follow-ups and device interrogations were
performed according to the routine practice of the participating
centres.10 TRENDS was an observational cohort study with patient eligi-
bility criteria and specified follow-upvisits. TRENDS study patients had to
have at least one stroke risk factor (including a history of congestive heart
failure, hypertension, age ≥65 years, diabetes mellitus, or prior stroke/
transient ischaemic attack); patients with replacement devices or long-
standing permanent AF were excluded. TRENDS patients were followed
with device interrogations every3months and clinic visits every6 months
for 2 years.7 Patients with a history of paroxysmal and persistent AF were
kept in the analysis cohort to reflect the spectrum of patients encoun-
tered in daily routine practice and to explore in depth the association
between device-detected AF and ischaemic stroke.
Data extraction
Data pooled across all three studies included the following baseline char-
acteristics: gender, AF classification (paroxysmal/persistent), prior
stroke, aspirin, antiplatelet and oral anticoagulation use, and CHADS2
scores [congestive heart failure, hypertension, age ≥75 years, diabetes,
prior stroke/transient ischaemic attack (TIA)] which were calculated
for all patients, with or without AF.11 Pooled data collected over the
course of patient and device follow-up visits included the number of
hours of AF burden detected each day and the occurrence of ischaemic
stroke or TIA events. For the Italian ClinicalServicew project and PANO-
RAMA study, diagnosis of ischaemic stroke and TIA events were based on
the judgement of the treating neurologist; without formal adjudication of
medical records by an independent reviewer. In TRENDS, ischaemic
stroke and TIA events were adjudicated through medical record
review by a committee of three neurologists.
Device-detection of atrial fibrillation burden
Patients had been previously implanted with devices (Medtronic, Inc.,
Minneapolis, MN, USA) capable of continuous AF detection and
monitoring by means of atrial lead and rate detection algorithms. In
TRENDS, the protocol specified that AF detection be programmed
to nominal settings (atrial rate .175 b.p.m. lasting ≥20 s). In the
ClinicalService and PANORAMA studies, nominal device settings were
usually applied. The sensitivity and specificity of device detection of AF
burden in Medtronic devices has been established in previous studies
and has been shown to exceed 95% for both measures.12 The number
of minutes of AF recorded in a day (i.e. daily AF burden) was used for ana-
lysis and in every patient themaximum daily AFburdenexperiencedduring
the follow-up was analysed. To investigate the prognostic value of AF
burden (i.e. maximum daily AF burden), a range of cut-off points were
defined a priori as 5 min, 1, 6, 12, and 23 h. Cut-off points were based on
previously reported thresholds (5 min, 6 and 23 h)4,7,8 with additional
cut-off points added to have a more complete characterization of the
consequences of AF burden. Patients with no AF burden or ,5 min of
AF burden were categorized as not having AF. A minimum threshold
of 5 min of AF burden was previously found to carry clinical rele-
vance4,6–8 and recently the ASSERT trial found that .6 min of AF were
associated with an increased risk of ischaemic stroke and systemic embol-
ism.13 The analysis of AF burden continued through our sequence of
thresholds to a threshold of 23 h where patients with at least 1 day with
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at least 23 h of AF burden detected were compared with patients who
experienced 0 to 23 h of AF burden as their maximum daily AF burden.
Statistical methods
Data are reported as median and inter-quartile range (IQR) or as number
and percentage, as appropriate. Person-years rates of ischaemic stroke and
ischaemic stroke plus TIA were calculated for categories of AF burden.
Analyses were restricted to patients with at least one follow-up visit and
at least 3 months of continuous device monitoring. Multivariable modelling
of ischaemic stroke risk was done using Cox regression models with time-
dependent covariates.14 In the first analyses, AF burden was entered as a
continuous time-dependent covariate. In this analysis, a patient’s AF
burden could increase but not decrease during the follow-up period.
This assumption is clinically justified by the prevalent concept that AF
carries a risk of ischaemic stroke independent on its reduction in fre-
quency/duration or its potential disappearance for some time. The
results are expressed as hazard ratios (HRs) with 95% confidence intervals
(95%CI),whichcanbe interpretedas the increase in risk foreachadditional
hour of AF burden experienced. In the second analysis, we used separate
Cox regression models where AF burden was entered as a dichotomized
time-dependent covariate where the status of the time-dependent indica-
tor variable changed at the moment the patient crossed the AF threshold
value. Once a patient has crossed the AF threshold being evaluated they
were considered exposed for the remainder of the follow-up period.
For each cut-off, ischaemic stroke and TIA events were compared
between patients with AF burden below that threshold and patients
with AF at or above that threshold. This approach diminishes the relative
increase in risk at higher thresholds but reflects the difference in event
rates between those above and below the threshold. We adjusted for
the CHADS2 stroke risk score and oral anticoagulation use at baseline;
both adjusted and unadjusted results are reported. Additionally, we also
adjusted for the CHADS2 score, oral anticoagulation use at baseline and
studycohort. Patientswerecensoredat the last dayofdevicedataavailable.
Statistical analyses were performed using the SAS software (version 9.3,
SAS Institute, Inc., Cary, NC, USA). No adjustments for multiplicity were
made and a two-tailed P, 0.05 was considered statistically significant.
Results
Baseline characteristics
At entry to the study, the median age was 70 years, and 31% were
female. A history of prior stroke was present in 6% of the patients
and 59% had a CHADS2 score of two or more. Additional baseline
characteristics in the aggregate and by individual study are presented
in Table 1.
Atrial fibrillation burden during
the follow-up
The median duration of follow-up was 24 months (IQR: 14–40
months). During the follow-up, 43% of patients experienced at
least 1 day with at least 5 min of AF burden detected. Among these
patients, the median time to the first day with at least 5 min of AF
was 2 months (IQR: 0.2–9.5) (Figure 1). Within the first 3 months,
24% of patients experienced at least 1 day with 5 min of AF, 18% at
least 1 h, 13% at least 6 h, 10% at least 12 h, and 6% experienced at
least 1 day with at least 23 h of AF.
Amongpatientsexperiencing at least 1 dayof AF burden during the
follow-up, the median time to the maximum AF burdenwas6 months
(IQR: 1.3–14). Figure 2 showsthe cumulative proportion over time of
patients reaching the day with the maximum observed daily AF
burden value during the follow-up. The characteristics of patients
at baseline according to the maximum daily AF burden experienced
during the follow-up are shown in Table 2.
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Table 1 Baseline characteristics by study
Total (n 5 10 016) PANORAMA (n5 3556) TRENDS (n5 2553) ClinicalService (n 5 3907)
Age, median years (IQR) 70 (61, 76) 69 (60, 76) 73 (64, 79) 68 (60, 74)
Male, n (%) 6859 (69) 2096 (59) 1694 (66) 3069 (79)
Diabetes mellitus, n (%) 2537 (25) 896 (25) 817 (32) 824 (21)
Hypertension, n (%) 5896 (59) 2116 (60) 1940 (76) 1840 (47)
Atrial fibrillation, n (%)
Paroxysmal 1923 (19) 784 (22) 678 (27) 461 (12)
Persistent 478 (5) 91 (3) 48 (2) 339 (9)
Oral anticoagulation, n (%) 1822 (18) 631 (18) 526 (21) 665 (17)
CHADS2 group, n (%)
CHADS2 0–1 4133 (41) 1684 (47) 722 (28) 1727 (44)
CHADS2 2–6 5883 (59) 1872 (53) 1831 (72) 2180 (56)
Prior stroke, n (%) 589 (6) 89 (3) 345 (14) 155 (4)
Device type
PM 4277 (43) 2726 (77) 1238 (49) 313 (8)
ICD 2004 (20) 404 (11) 822 (32) 778 (20)
CRT 3735 (37) 426 (12) 493 (19) 2816 (72)
IQR, inter-quartile range; PM, pacemaker; ICD, implantable cardiac defibrillator; CRT, cardiac resynchronization therapy.
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Risk of ischaemic stroke and transient
ischaemic attack events associated with
atrial fibrillation burden during the
follow-up
During the follow-up, 95 patients experienced an ischaemic stroke or
TIA for an annualized rate of 0.39% per year; 57 events were ischae-
mic strokes (rate of 0.23% per year). Figure 3 shows the distributionof
patients and the unadjusted event rates according to maximum AF
burden.
Increasing AF burden was significantly associated with increasing
age and the CHADS2 score and presence of prior stroke (P,
0.001 for all, see Table 2). Among the observed ischaemic strokes,
26 (46%) had experienced at least 5 min of AF burden prior to the
event. Of the 2401 patients with a reported history of AF at enrol-
ment, 32% did not meet the 5 min AF burden threshold during the
follow-up.
In Supplementary material online, Table S2 event rates (stroke and
stroke + TIA) by study are shown. The rate of strokes or strokes +
TIA was particularly low in the ClinicalService population, who com-
pared with the other studies had a higher proportion of patients
taking anticoagulants during the follow-up.
Risk of ischaemic stroke and transient
ischaemic attack events associated with
atrial fibrillation burden: continuous
analysis
We sought to define the HR for ischaemic stroke at any given
maximum AF burden. To this end, we modelled ischaemic stroke
risk with AF burden entered as a continuous variable. After adjust-
ment for the CHADS2 score and oral anticoagulation at baseline,
therewas a significant association between daily AF burden modelled
Figure 2 Cumulative proportion over time of patients reaching
the day with the maximum observed daily atrial fibrillation burden
value during the follow-up, among patients experiencing at least 1
day of atrial fibrillation burden (n ¼ 4287).
Figure 1 Atrial fibrillation burden along with time during the
follow-up. Kaplan–Meier curve of patients experiencing a first
day with at least 5 min of atrial fibrillation burden, among all subjects
(n ¼ 10 016).
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Table 2 Baseline characteristics by maximum atrial fibrillation burden experienced during the follow-up
No AF burden
to <5 min of AF
burden
≥5 min to
<1 h of AF
burden
≥1 h to <6 h
of AF burden
≥6 h to <12 h
of AF burden
≥12 hto <23 h
of AF burden
≥23 h of
AF burden
P-value
n ¼ 5729 n ¼ 932 n ¼ 814 n ¼ 465 n ¼ 520 n ¼ 1556
Age, median years (IQR) 69 (60, 76) 66 (56, 75) 71 (63, 78) 71 (63, 78) 70 (63, 76) 72 (65, 77) ,0.001
Male, n (%) 3892 (68) 624 (67) 522 (64) 309 (67) 364 (70) 1148 (74) ,0.001
Diabetes mellitus, n (%) 1515 (27) 212 (23) 193 (24) 112 (24) 126 (24) 379 (24) 0.118
Hypertension, n (%) 3414 (60) 471 (51) 455 (56) 279 (60) 330 (64) 947 (61) ,0.001
Atrial fibrillation, n (%) ,0.001
Paroxysmal 678 (12) 106 (11) 204 (25) 142 (31) 215 (41) 576 (37)
Persistent 104 (2) 17 (2) 25 (3) 22 (5) 31 (6) 279 (18)
Oral anticoagulation, n (%) 778 (14) 145 (16) 130 (16) 86 (19) 135 (26) 548 (35) ,0.001
CHADS2 group, n (%) ,0.001
CHADS2 0–1 2357 (41) 467 (50) 344 (42) 185 (40) 210 (40) 570 (37)
CHADS2 2–6 3372 (59) 466 (50) 470 (58) 280 (60) 310 (60) 986 (64)
Prior stroke, n (%) 320 (6) 33 (4) 49 (6) 28 (6) 32 (7) 127 (8) ,0.001
Patients were classified according to maximum AF burden experienced prior to stroke. AF, atrial fibrillation; IQR, inter-quartile range.
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as a continuous variable and ischaemic stroke events with an HR ¼
1.03 per h (95% CI: 1.00–1.05, P ¼ 0.040). To calculate the HR for
any given increase the following formula can be applied:
Hazard ratio = Exponential (0.0263
× AF burden daily maximum hours).
This result implies that the HR for a maximum AF burden of 6 h was
1.17 (95% CI: 1.01–1.36) and for 12 h the HR was 1.37 (95% CI:
1.01–1.85).
The results were similar for ischaemic stroke and TIA events with
an expected HR, for a 6 h AF burden ¼ 1.14 (95% CI: 1.02–1.28) and
for a 12 h AF burden ¼ 1.30 (95% CI: 1.03–1.65).
Risk of ischaemic stroke and transient
ischaemic attack events associated with
atrial fibrillation burden: analysis by
dichotomized cut-off thresholds of atrial
fibrillation burden
By means of a series of Cox regression models, we explored the as-
sociation of pre-defined thresholds of AF burden and ischaemic
stroke, controlling for the CHADS2 score and anticoagulation use
at baseline. The ischaemic stroke HR point estimates were similar
for all the thresholds examined, but the highest point estimate was
observed for a threshold ≥1 h with an HR of 2.11 (95% CI: 1.22–
3.64, P ¼ 0.008). The threshold of ≥5 min was also statistically sig-
nificantly associated with the occurrence of ischaemic stroke,
HR ¼ 1.76 (95% CI: 1.02–3.02, P ¼ 0.041). Atrial fibrillation
Figure 3 Distribution of patients according to maximum atrial fibrillation burden experienced during the follow-up. Stroke and transient
ischaemic attack events and event rates are given in the table below the figure. Events were classified according to maximum atrial fibrillation
burden experienced prior to event occurrence.
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Figure4 The Forest plot of unadjustedhazard ratios for (A) stroke events and (B) strokeor transient ischaemic attackevents. Dotted line indicates
line of unity (HR ¼ 1.0) with dots above the line showing increased risk of stroke or (stroke or TIA); bars represent 95% CIs.
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thresholds of ≥6, ≥12, and ≥23 h did not reach statistical signifi-
cance: 6 h HR ¼ 1.74 (95% CI: 0.96–3.41, P ¼ 0.067), 12 h HR ¼
1.72 (95% CI: 0.92–3.22, P ¼ 0.090), and 23 h HR ¼ 1.44 (95% CI:
0.69–3.01, P ¼ 0.332) (Figure 4A).
Different thresholds of AF burden were also associated with the
risk of the composite of ischaemic stroke and TIA. In detail, AF
burden threshold ≥5 min had an HR ¼ 2.04 (95% CI: 1.34–3.09,
P, 0.001), ≥1 h had an HR ¼ 1.90 (95% 1.25–2.90, P ¼ 0.003),
≥6 h had an HR ¼ 1.53 (95% CI: 0.97–2.41, P ¼ 0.065), ≥12 h
had an HR ¼ 1.51 (95% 0.93–2.44, P, 0.092), and ≥23 h had an
HR ¼ 1.51 (0.88–2.56, P ¼ 0.132) (Figure 4B).
To minimize the confounding factor of anticoagulation, we per-
formed an additional analysis excluding patients on oral anticoagula-
tion (OAC) at baseline, as well as excluding patients on OAC at
baseline and adjusting for the CHADS2 score. The results of this ana-
lysis, performed on 8122 patients (Table 3), confirm an increased risk
of stroke and stroke + TIA for a device-detected AF burden≥1 h vs.
a device-detected AF burden,1 h, with HR between 1.89 and 2.09.
When adjusting for study cohort, effect sizes remained similar (AF
burden threshold ≥1 h for stroke had an HR ¼ 1.88 (95% CI: 1.08–
3.29, P ¼ 0.026) and AF burden threshold≥1 h for stroke or TIA had
an HR ¼ 1.60 (95% CI: 1.03–2.46, P ¼ 0.034).
Discussion
Our pooled analysis shows that in relatively unselected population of
patients with an arrhythmia detecting CIED in place, daily AF burden
is associated with an increased risk of ischaemic stroke or TIA even
after adjustment for oral anticoagulants use and CHADS2 score.
These data add to the current evidence that measuring daily AF
burden may have important clinical relevance13 and support the
search for specific thresholds of AF burden associated with a substan-
tial increase in the risk of ischaemic stroke.15 We found that for every
additional hour increase in the daily maximum of AF burden the rela-
tive risk for stroke increases by 3%. A daily maximum of 6 h AF
burden implies an increase in risk of stroke of 17% and a 12 h
AF burden implies a 37% increase in risk. When we analysed AF
burden as a dichotomized outcome, a threshold of ≥1 h gave the
strongest results.
The ASSERT study analysed the risk associated with the occur-
rence of any AF in the first 3 months of observation and found that
device-detected AF lasting only 6 min in duration was associated
with a 2.5-fold increase in the riskof ischaemic stroke or systemic em-
bolismovera follow-upof2.5 years.13 Our studydiffers fromASSERT
because our study population is less selected (only 29% were
ASSERT-like, i.e. age .65, no previous AF and hypertensive). Our
analysis offers a complementary approach as it was focused not
only on the risk associated with AF detected in the first 3 months
of observation, but considered AF occurring at any time during the
follow-up. This approach may be clinically relevant since patients
may develop or reach the maximum AF burden at varying time inter-
vals during the observation period, with a median time to the
maximum AF burden of 6 months (Figure 1). According to this
finding, our study provides an analysis of the clinical implications of
device-detected AF burden with a wider clinical perspective com-
pared with ASSERT,13 where the focus was on the implications of
AF burden detected in the first 3 months of observation.
With the advent of CIEDs that have improved arrhythmia detection
algorithms and memory capabilities, as well as the advent of remote
monitoring, there is frequent detection of episodes of AF of variable
duration, usually silent in device clinics.2 The diagnostic accuracy of
pacemaker and ICDs with an atrial lead is very high, with appropriate
detection of 95% of AF episodes,12 while for implantable loop recor-
ders, not included in this data set, the specificity is 85%.16 A recent
editorial commenting on the clinical implications of device-detected
AF according to ASSERT findings15 pointed out that there is need to
identify precise thresholds of AF burden associated with clinically rele-
vant increases in the risk of stroke. The assessment of AF burden
thresholds associated with increasing risks of stroke is important and
our study provides a contribution in the field.
Clinical decisions regarding the prescription of antithrombotic
prophylaxis are based on risk stratification, frequently using the
CHADS2 score and an assessment of the individual’s bleeding risk,
as well as patient preferences.17– 19 Our continuous analysis helps
to assess the additional impact of quantified AF burden on stroke
risk in patients with AF. Moreover, quantified AF burden provided
by implanted devices may be clinically important, since it has been
observed that providing physicians with timely information on AF
burden may result in an increased prescription of appropriate antith-
rombotic prophylaxis.20 Our dichotomized analysis shows that after
adjustment for the CHADS2 score and oral anticoagulants use,
device-detected AF burden is associated with an increased risk of
stroke; of the several cut-points evaluated, the 1 h threshold
appears to be the most robust with a doubling in the risk of stroke.
Choice of a potential threshold of AF burden associated with an
increased risk of stroke remains problematic. As a matter of fact,
when increasing the duration of AF burden (i.e. to 12 or 23 h) the dis-
criminatory capability is lost, probably because the risk is consistent
also below the proposed threshold. The prognostic implications of
AF burden ,5 min are at present unknown for patients carrying a
pacemaker or an implantable defibrillator.
We recognize that our study has limitations. There may be con-
founding factors associated with AF burden that we have not
accounted for in our analyses, for example, the differences in follow-
up timing between the three studies. In our study, the absolute event
rate of ischaemic stroke was low, perhaps reflecting a general trend
towards lower rates of ischaemic strokes in comparison with what
predicted by CHADS2, a score validated .10 years ago in a group
of patients with a mean age of 81 years derived from the National
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Cox regression analysis performed on 8122
patients without oral anticoagulation at baseline,
adjusted for the CHADS2 score
Total Events HR for AF
burden ≥1 h vs.
<1 h (95% CI)
P-value
Stroke 8122 44 2.09 (1.10, 3.96) 0.0239
Stroke + TIA 8122 69 2.05 (1.24, 3.39) 0.0051
Adjusting for CHADS2 score
Stroke 8122 44 1.90 (1.00, 3.61) 0.0487
Stroke + TIA 8122 69 1.89 (1.14, 3.12) 0.0135
TIA, transient ischaemic attack; HR, hazard ratio; CI, confidence interval.
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Registry of Atrial Fibrillation, with a high prevalence of heart failure.21
It is noteworthy that also in ASSERT,13 the actual risk of stroke in
patientswith device-detected AFwasmuch lower than that expected
by the CHADS2 score, possibly reflecting a general temporal trend
towards a progressive reduction incidence of stroke in developed
countries.22,23 Moreover, the low rate of ischaemic strokes observed
even among patients experiencing sizable AF burdens may reflect the
long periods of sinus rhythm experienced by our patients and better
treatment of stroke risk factors. In addition, some degree of under-
reporting of ischaemic stroke and TIA events cannot be ruled out
with the study designs used and this has to be considered in the clin-
ical interpretation of the rather low stroke rates.
Stroke risk can also be reduced by use of anticoagulants, whose im-
plementation is more common in higher CHADS2 categories. We
accounted for the use of anticoagulants in our multivariable models
and also by excluding patients on anticoagulants in a secondary ana-
lysis. In these additional analyses, performed by excluding patients on
anticoagulants at baseline, as well as by excluding patients on OAC at
baseline and adjusting for the CHADS2 score, the significantly
increased risk of stroke and stroke + TIA for a device-detected AF
burden ≥1 h vs. a device-detected AF burden ,1 h was confirmed,
with HR between 1.89 and 2.09.
In summary, our results show that monitoring AF burden continu-
ously (made possible by the information from an implanted device)
may allow timely evaluation of the risk of ischaemic stroke faced by
patients with AF. Its comprehensive nature avoids the problem of
missedepisodesof AF inherent in intermittent monitoring fordetect-
ing clinically silent AF. It is noteworthy that in our population of over
10 000 patients the day with the maximum AF duration occurred
after a mean of 6 months of monitoring. On-going and future
studies, also using remote transmission of data on AF burden, will
allow more precise assessment of the ways to integrate information
on specific levels of AF burden (i.e. ≥1 h) into clinical decision-
making tailored to reduce stroke risk.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Twiddler syndrome causing an inappropriate implantable cardioverter-
defibrillator shock
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A 72-year-old man was implanted
with a dual-chamber cardioverter de-
fibrillator (Lumax 540-HFT, Biotronik,
Germany, Berlin) in secondary preven-
tion. An atrial active fixation lead (Bio-
tronik Solia S53) and a ventricular
active fixation lead (Biotronik Linox
S65) were used. Predischarge an X-ray
showed a good position of both leads
(Panel A) and the internal cardioverter
defibrillator was checked and func-
tioned correctly. The patient was fol-
lowed on remote monitoring (Home
Monitoring network, Biotronik SE &
Co. KG). Before the first planned
in-clinic follow up, we received an
alert due to the delivery of a shock
for a ventricular arrhythmia and an episode of atrial fibrillation. All atrial and ventricular leads parameters seemed stable. Analysing the
electrogram (EGM) (Panel B), we recognized an episode of atrial fibrillation on the atrial EGM. The ventricular EGM showed intermittent
irregular rapid activity, with obvious similarity to the atrial rhythm. This could be explained byeither intermittent 1:1 conduction of AFor by
intermittent cross-talk with oversensing of the atrial signal on the ventricular lead. The patient was admitted and a chest X-ray confirmed
displacement of the ventricular lead in the right atrium caused bya Twiddler syndromewith twistingof the leads in the pocket (Panel C). The
patient denied conscious manipulation of the device pocket, but reported ‘spontaneous’ rotation of the device. A second intervention was
consequently performed, electrodes were completely twisted (Panels D and E) and the ventricular lead showed signs of insulation break.
Both leads were extracted and replaced. The generator was fixed in the pocket with a ligature.
(A) Chest X-ray at before discharge. (B) Stored EGM of the episode. From top to bottom are atrial and ventricular marker channel,
atrial EGM, and ventricular EGM. Correct detection of an episode of atrial fibrillation (black circle—AF onset) and inappropriate detection
of ventricular fibrillation leading to inappropriate therapy. (C) Chest X-ray showing displacement of the ventricular lead in the right atrium
and twisted leads. (D and E) Twisted leads during repositioning.
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